z-logo
open-access-imgOpen Access
Research protocol for study of efficacy of Vruntaka Phala Beeja (Solanum malongena Linn.) Swarasa in Dhatura Beeja (Datura metel Linn.) poisoning in Wistar rats
Author(s) -
Meghsham P. Anjankar,
Sonali Chalakh
Publication year - 2022
Publication title -
international journal of health sciences (ijhs) (en línea)
Language(s) - English
Resource type - Journals
eISSN - 2550-6978
pISSN - 2550-696X
DOI - 10.53730/ijhs.v6ns2.5059
Subject(s) - antidote , medicine , datura , traditional medicine , protocol (science) , clinical efficacy , clinical toxicology , pharmacology , toxicology , toxicity , surgery , biology , pathology , alternative medicine , psychiatry
Background: In the treatment protocol of poisoning, antidotes are mainly used to counter the poisons. In Ayurveda, antidotes are termed as agada or vishaghna dravyas which either directly neutralize the poison or counter its deleterious effects. In Ayurveda various agada (antidote) formulations are mentioned out of which few are being used in clinical practice due to insufficiency in available research data. Vruntakphala beeja Swarasa (VPBS) is one of the antidote formulations described in Anupana Manjiri and Rasajalanidhi, which is mentioned as effective against ingested Dhatura Beeja (DB) poisoning. Currently no clinical as well as preclinical data is available about its efficacy. Aim and Objective: To study efficacy of Vruntaka Phala Beeja (Solanum malongena Linn.) swarasa in Dhatura Beeja (Datura metel Linn.) poisoning in Wistar rats. Methodology: 36 Wistar rats equally classified into 6 groups will be subjected to DB poisoning except normal control group. Efficacy study of VBPS will be carried out on experimental groups as per standard protocol. Results: Clinical toxicity signs, Sr. biochemical and Histopathological observations from all groups will be observed. Conclusion: Conclusion will be drawn strictly on the basis of results.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here